Entera Bio and OPKO Biologics have joined forces in a research collaboration to advance the development of oral peptide tablet formulations designed to address obesity and intestinal malabsorption syndromes.
Under the terms of agreement, OPKO will provide its exclusive long-acting GLP-2 peptide along with specific analogs of Oxyntomodulin (OXM) to be used in the creation of oral tablet formulations, leveraging Entera's specialised oral delivery technology.
This collaboration with OPKO signifies a significant step in expanding the application of oral delivery technology to encompass a wider range of valuable peptides.
It is challenging to administer peptides orally due to their rapid degradation within the gastrointestinal tract and limited permeability. GLP-2 analogs have demonstrated the ability to enhance nutrient absorption in patients afflicted with short bowel syndrome (SBS) and subsequently reduce their reliance on parenteral support.
The current FDA-approved GLP-2 analog, Teduglutide, necessitates daily subcutaneous injections. In SBS patients, oral drug delivery is especially problematic, as the absorptive capacity of the intestine is diminished due to its shortened length and reduced functionality.
